Caspar da Cunha‐Bang

Author

Also Known As

C da Cunha Bang, C da Cunha-Bang, C. Da Cunha-Bang, C. da Cunha-Bang, C. da Cunha‐Bang, Caspar Da Cunha Bang, Caspar Da Cunha-Bang, Caspar Da Cunha‐Bang, Caspar da Cunha Bang, Caspar da Cunha-Bang

137

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Rigshospitalet Copenhagen University Hospital University of Copenhagen Odense University Hospital Centre of Excellence for Health, Immunity and Infections

About

Caspar da Cunha‐Bang is an author at Rigshospitalet specializing in medicine, transplantation, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	167
2	Health Sciences	3	3	70
3	Epidemiology	2	2	69
4	Public Health	1	1	18
5	Gastroenterology	1	1	28

Caspar da Cunha‐Bang

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater, New England Journal of Medicine	2023	268
Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients Caspar da Cunha‐Bang, Jacob Simonsen, Klaus Rostgaard, Blood Cancer Journal	2016	72
Patients with CLL have a lower risk of death from COVID-19 in the Omicron era Carsten Utoft Niemann, Caspar da Cunha‐Bang, Marie Helleberg, Blood	2022	67
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial Moritz Fürstenau, Arnon P. Kater, Sandra Robrecht, The Lancet Oncology	2024	59
Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death Emelie Curovic Rotbain, Carsten Utoft Niemann, Klaus Rostgaard, Leukemia Individual ComorbiditiesLymphoid NeoplasiaHematological MalignancyEpidemiologyChronic Lymphocytic Leukemia	2021	51
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations Moritz Fürstenau, Yvonne J. Thus, Sandra Robrecht, Blood	2023	35
IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study Emelie Curovic Rotbain, Henrik Frederiksen, Henrik Hjalgrim, Haematologica Chronic Lymphocytic LeukemiaMixed-phenotype Acute LeukemiaImmunodeficienciesImmunologyPathology	2019	34
A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater, Blood	2021	33
Richter’s transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study Yasmin Ben-Dali, Mariam Hussein Hleuhel, Caspar da Cunha‐Bang, Leukemia & lymphoma/Leukemia and lymphoma	2020	32
Deep targeted sequencing of <i>TP53</i> in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment Christian Brieghel, Savvas Kinalis, Christina W. Yde, Haematologica	2018	30

Page 1